About Phoenix Biotechnology
Phoenix Biotechnology is a Healthcare company based in San Antonio (United States) founded in 2003. Plant-based therapies for cancer and neurodegenerative diseases are developed. Phoenix Biotechnology has raised $12.84 million across 6 funding rounds. Phoenix Biotechnology offers products and services including PBI-05204, PBI-01207, and PBI-04711. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its legal entity is Inc. Its competitors include Moderna, BeiGene and Biogen; 3 of its 3 listed competitors have raised funding.
Company details
Phoenix Biotechnology was established in 2003 in San Antonio, United States, within the biotechnology sector. Plant-derived therapies targeting cancer and neurodegenerative diseases are developed by the company. Operations focus on extracting active compounds from sources like Nerium oleander, with the lead product PBI-05204 advancing through Phase II trials for solid tumors. Research emphasizes binding to cellular targets in oncology applications.
- Headquarters San Antonio, United States
- SectorsHealthcare
- Website phoenixbiotechnology.com
- Social LinkedIn
- Legal Name Inc
- Total Equity Funding$12.84M (USD)
in 6 rounds
- Latest Funding Round$5M (USD), Series B
Aug 2020
Products & Services of Phoenix Biotechnology
Phoenix Biotechnology offers a comprehensive portfolio of products and services, including PBI-05204, PBI-01207, and PBI-04711.
Natural extract for cancer and viral disease treatment.
Product targeting neurodegenerative diseases.
Extract for neuroprotection and disease management.
Funding Insights of Phoenix Biotechnology
Phoenix Biotechnology has successfully raised a total of $12.84M across 6 strategic funding rounds. The most recent funding activity was a Series B round of $5 million completed in August 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $12.84M
- Total Rounds 6
- Last Round Series B — $5M
- First Round $3.3M
(Dec 2010)
All 6 funding rounds of Phoenix Biotechnology with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2020 | $5M | Series B | – | – | – |
| Oct 2019 | $1.76M | Series A | – | – | – |
| Jan 2019 | $1.05M | Series A | – | – | – |
| Jul 2018 | $879,000 | Series A | – | – | – |
| Jun 2014 | $852,000 | Series A | – | – | – |
| Dec 2010 | $3.3M | Series A | – | – | – |
People of Phoenix Biotechnology
12 people are tracked at Phoenix Biotechnology (2 in leadership, 10 in board & advisors).
| Name | Role | Group |
|---|---|---|
Lou Kost | Co-Founder, Acting CEO, President, Secretary & Director | Leadership |
Joseph Nester | COO | Leadership |
MacDonald T. Haskell | Director | Board & advisors |
Jeffrey Thompson | Director | Board & advisors |
Crandell Addington | Co-Founder, Chairman & Director | Board & advisors |
Robert A. Newman | CSO & Chairman, Scientific Advisory | Board & advisors |
Shawn J. Green | Director | Board & advisors |
Rick Matos | Director | Board & advisors |
Andrew J. Butler | Director | Board & advisors |
Jagan Sastry | Scientific Advisor | Board & advisors |
Keith I. Block | Scientific Advisor | Board & advisors |
Peiying Yang | Scientific Advisor | Board & advisors |
Complete people profiles for Phoenix Biotechnology
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Phoenix Biotechnology
3 dated milestones of Phoenix Biotechnology across 17 years, from founding to its latest funding, stage changes and deals.
- Founded Phoenix Biotechnology is founded.
- Funding First funding round of $3.3M.
- Funding Latest funding round, Series B, of $5.0M.
Competitors of Phoenix Biotechnology
Phoenix Biotechnology has 3 listed competitors in our database, 3 of them funded. They include Moderna, BeiGene and Biogen.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| biogen.com | 1978 | Cambridge, United States | $80M | 1 | Therapies for neurodegenerative and immunology disorders are developed. |
Detailed competitors of Phoenix Biotechnology
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Phoenix Biotechnology
Websites that share an audience with Phoenix Biotechnology (phoenixbiotechnology.com).
Websites whose visitors overlap most with Phoenix Biotechnology. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
seedbiotech.com | seedbiotech.com | 100% | – | ||
| vgxii.com | 100% | 2.9K | #6,447,856 | View details | |
| xbiotech.com | 96% | 3.9K | #4,929,272 | View details | |
hope.bio | hope.bio | 95% | #5,286,702 | – | |
| cellingbiosciences.com | 94% | View details | |||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 6 similar websites and full traffic analytics for Phoenix Biotechnology
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 6 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Neurology
3 companies that operate in the same segment as Phoenix Biotechnology (Neurology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Phoenix Biotechnology
Complete news archive for Phoenix Biotechnology
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Phoenix Biotechnology
Phoenix Biotechnology was founded in 2003 and raised its 1st funding round 7 years after it was founded.
Phoenix Biotechnology is headquartered in San Antonio, United States. It is registered at San Antonio, Texas, United States.
Phoenix Biotechnology is a funded company, having raised a total of $12.84M across 6 funding rounds to date. The company's 1st funding round was a Series A of $3.3M, raised on Dec 2010.
Phoenix Biotechnology was established in 2003 in San Antonio, United States, within the biotechnology sector. Plant-derived therapies targeting cancer and neurodegenerative diseases are developed by the company. Operations focus on extracting active compounds from sources like Nerium oleander, with the lead product PBI-05204 advancing through Phase II trials for solid tumors. Research emphasizes binding to cellular targets in oncology applications.
Phoenix Biotechnology offers PBI-05204, PBI-01207, and PBI-04711.
Phoenix Biotechnology operates through Inc.